The public offerings follow a positive readout, which the firm announced earlier Monday, from a Phase III registrational trial of its lead candidate daraxonrasib.

The firm said its pan-RAS inhibitor daraxonrasib demonstrated a statistically significant improvement in survival outcomes in a registrational trial, regardless of RAS mutation status.

The firm aims to develop siRNAs and antisense oligonucleotides for common diseases that require targeting tissues beyond the liver.

Telix could gain up to $2.1 billion in the deal, in which it will aid Regeneron in developing four initial therapies with the option to advance four more.

At a first meeting on pediatric gene and cell therapy trials, participants discussed when enrolling children before adults is ethical and when to wait.

Precision Medicine Online's seventh annual survey shows precision oncology programs didn't go unscathed as the Trump administration slashed research funding and canceled projects.

NEW YORK – Oricell Therapeutics on Thursday said it has raised $110 million in a pre-initial public offering financing round as it looks to break into international markets. The Shanghai-based company ...

Astellas Pharma will pay Dyno a license fee to use its engineered AAV capsid, as well as possible milestone payments and royalties.

Through a six-month pilot program at Pacific Cancer Care, the firms are assessing if they can improve guidelines-backed ...

The firm will use the funds, which now total around $46 million, to advance the CDK2 inhibitor INX-315 in CDK4/6 inhibitor-resistant breast and ovarian cancers.

NEW YORK – Acurion has raised $4.3 million in seed funding to further establish its OncoGaze digital pathology platform's ability to detect biomarkers from cancer hematoxylin and eosin slides and ...